Answers are grounded in this paper and cite their sources.
An expert panel discusses the role of digital health solutions in monitoring adherence to growth hormone therapies among patients and healthcare professionals.
Digital health solutions have evolved for managing long-term treatment with recombinant human growth hormone, making it essential to understand their features and functionalities for adoption and acceptance by healthcare professionals (HCPs), patients and caregivers. Findings from a participatory workshop in Hong Kong explored HCPs' perspectives on monitoring adherence to growth hormone (GH) therapies using digital health solutions incorporating Aluetta® with Smartdot™ and Growzen™ ecosystem (Merck Healthcare KGaA, Darmstadt, Germany). These insights can empower HCPs to effectively integrate and recommend digital health solutions during GH treatment, fostering successful treatment strategies for patients with growth hormone deficiency.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: